Home/Pipeline/Undisclosed Oral Combination Therapy

Undisclosed Oral Combination Therapy

Pain (specific type undisclosed)

Phase 1Active

Key Facts

Indication
Pain (specific type undisclosed)
Phase
Phase 1
Status
Active
Company

About Amalgent Therapeutics

Amalgent Therapeutics is a private, clinical-stage company founded in 2020 to address the global challenge of severe pain and the safety limitations of current medications. Its innovative approach centers on developing novel combination therapies from existing drugs, aiming to dramatically improve the therapeutic window and safety profile of pain management. Operating from Cambridge, MA, the company is positioned in the high-need but risky space of non-opioid pain therapeutics, with a pipeline of oral candidates intended for the US market.

View full company profile

Therapeutic Areas